Jim Cramer on Novo Nordisk (NVO): ‘Be Careful’ Amid Trump Impact
Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...
Italy's MPS shares fall ahead of Mediobanca board meeting on bid
Shares in Monte dei Paschi (MPS) fell again on Monday, extending Friday's losses, signaling lingering investor doubts over ...
Sectors Up Close: 'Lots of competitors' to Novo Nordisk in healthcare stocks
Obesity drugs - especially Novo Nordic's Ozempic - dominated healthcare headlines in 2024, but Matt Miskin of John Hancock ...
Take Five: Fed, ECB - and more from Trump
LONDON (Reuters) -It's a big week ahead as the U.S. Federal Reserve, European Central Bank and Bank of Canada hold their first meetings of 2025. Into the mix go earnings from heavyweights including ...
Stock market today: Asian markets are mixed after Wall Street edges back from its record
Shares were mixed in thin Asian trading on Monday after U.S. stocks edged back from their all-time high. Oil prices fell and ...
Dollar dips as Donald Trump eases stance on China tariffs
The dollar dropped to a one-month low after President Donald Trump appeared to soften his approach toward tariffs on China.
S&P 500 ekes out intraday record before ending down with Dow, Nasdaq on mixed company news
US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...
STAT5d
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.